BioSpace News Archive

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it will be presenting two preclinical posters at the EORTC-NCI-AACR (“ENA”) annual meeting to be held October 26-28, 2022.

TransCode Therapeutics, Inc., an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma.

XORTX Therapeutics Inc. is pleased to announce receipt of a further no objection letter from Health Canada regarding the Company’s ongoing XRX-OXY101 clinical bridging pharmacokinetics study.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 9, 2022.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, announced the publication of the 24-month analysis from the BRAVO Study in Annals of Medicine and Surgery.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the start of enrollment of the first patient cohort (n=4) in its Intermediate Size Patient Population Expanded Access Program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis (SPMS) patients.

Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2022 on Wednesday, Nov. 2 at 9 a.m., ET.

Cigna Corporation, a global health service company, unveiled new insights from the Evernorth Vitality IndexTM, the largest study on the state of vitality, health and productivity in America.

Compugen Ltd. (Nasdaq: CGEN) announced today that it will present new clinical data from its COM701/nivolumab with or without BMS-986207 combination studies in patients with platinum resistant ovarian cancer and data from COM701 with or without nivolumab study in patients with metastatic NSCLC as poster presentations at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) congress taking place between December 7-9, 2022, in Geneva, Switzerland.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) today announced preclinical data characterizing its fourth-generation epidermal growth factor receptor (EGFR) inhibitor, THE-349, will be detailed in a live poster presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (ENA).